Literature DB >> 10673844

Is continued weight gain inevitable in type 2 diabetes mellitus?

J M Tremble1, D Donaldson.   

Abstract

Prevention and treatment of obesity are major clinical problems encountered in the management of Type 2 diabetes mellitus (DM); indeed, up to 90% of such patients are regarded as being overweight. Except for a brief period following diagnosis, when presumably enthusiasm to adopt lifestyle change is at its greatest, weight gain is generally progressive unless severe hyperglycaemia or complications intervene. Even a relatively modest weight loss of 10% can have major benefits in terms not only of reducing the risk of developing DM in the first place, but also in improving metabolic control after the disorder has become established. Behavioural therapy (BT) in combination with hypocaloric diet achieves weight loss in the short-term, but is poorly sustained in the long-term. Exercise has metabolic benefits beyond its rather minimal effects on short-term weight loss in that it may also aid long-term weight control. The difficulties encountered in maintaining lifestyle change do, however, suggest the need for ongoing intervention--perhaps including a regular period on a stricter dietary regimen (800-1000 kcalday-1), possibly a very low calorie diet (VLCD)(< 800 kcalday-1) or even the use of orlistat, a pancreatic lipase inhibitor which reduces the absorption of dietary fat. Realistically, the aim should be for long-term weight stability.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10673844     DOI: 10.1177/146642409911900406

Source DB:  PubMed          Journal:  J R Soc Promot Health        ISSN: 1466-4240


  7 in total

Review 1.  Orlistat: in the prevention and treatment of type 2 diabetes mellitus.

Authors:  G M Keating; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Antidiabetic medications and weight gain: implications for the practicing physician.

Authors:  Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2009-06       Impact factor: 4.810

Review 3.  Defining the role of insulin detemir in Basal insulin therapy.

Authors:  Javier Morales
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 4.  Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.

Authors:  Kjeld Hermansen; Lene S Mortensen
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

5.  Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study.

Authors:  S Martin; H Kolb; J Beuth; R van Leendert; B Schneider; W A Scherbaum
Journal:  Diabetologia       Date:  2003-11-05       Impact factor: 10.122

Review 6.  Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected].

Authors:  Abdul Basit; Musarrat Riaz; Asher Fawwad
Journal:  Vasc Health Risk Manag       Date:  2012-08-15

7.  Physician and patient management of type 2 diabetes and factors related to glycemic control in Spain.

Authors:  Nicole Rae Yurgin; Kristina Secnik Boye; Tatiana Dilla; Núria Lara Suriñach; Xavier Badia Llach
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.